Price of drugs for chronic myeloid leukemia (CML), reflection of the unsustainable cancer drug prices: perspective of CML Experts

1182/blood-2013-03-490003

ABSTRACT
As a group of more than 100 experts in chronic myeloid leukemia (CML),
we draw attention to the high prices of cancer drugs, with the particular
focus on the prices of approved tyrosine kinase inhibitors for the treatment
of CML. This editorial addresses the multiple factors involved in cancer
drug pricing, their impact on individual patients and healthcare policies, and
argues for the need to lower the prices of cancer drugs to allow more
patients to afford them and to maintain sound long-term healthcare policies.

http://bloodjournal.hematologylibrary.org/content/early/2013/04/23/blood...